Adaptive Biotechnologies Corpor
16.80-0.10 (-0.59%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · ADPT · USD
Key Stats
Market Cap
2.56BP/E (TTM)
-Basic EPS (TTM)
-0.81Dividend Yield
0%Recent Filings
8-K
Adaptive ends Genentech pact
Adaptive Biotechnologies terminated its 2018 strategic collaboration and license agreement with Genentech on August 13, 2025, effective February 9, 2026, ending joint work on cancer cell therapies. The move frees Adaptive from oncology exclusivity, allowing broader pursuits, while it books $33.7 million in non-cash revenue from prior payments during late 2025. Termination winds down activities smoothly. Yet Adaptive presses on with TCR prediction models and autoimmunity programs, targeting $25–$30 million Immune Medicine cash burn for 2025.
10-Q
Q2 FY2025 results
Adaptive Biotechnologies posted Q2 revenue of $58.9M, up 36% y/y from $43.2M, driven by MRD service revenue climbing 38% y/y to $44.4M on 37% higher clonoSEQ test volume, while regulatory milestones added $5.5M. Gross margin improved to 69.4% from 55.3%, reflecting lower cost of revenue at $18.0M, yet operating loss narrowed to $25.0M from $47.3M as expenses fell 7% y/y. Diluted EPS of -$0.17 beat last year's -$0.31, reconciling to 152M weighted shares with no anti-dilution effects. Cash and equivalents stood at $43.2M, with $222M total liquidity offsetting $133.6M revenue interest debt; free cash flow not disclosed in the 10-Q. MRD now dominates at 85% of revenue. Regulatory hurdles could still trip up milestone timing.
8-K
Q2 revenue beats, MRD profitable
Adaptive Biotechnologies reported Q2 2025 revenue of $58.9 million, up 36% year-over-year, driven by MRD segment growth of 42% to $49.9 million, which turned profitable with $1.9 million adjusted EBITDA. clonoSEQ test volume surged 37% to 25,321, bolstered by Flatiron integration and NovaSeq X Plus implementation. The company raised full-year MRD guidance to $190-200 million and cut cash burn to $45-55 million. MRD now dominates at 85% of revenue.
8-K
Shareholders back key proposals
Adaptive Biotechnologies Corporation's shareholders overwhelmingly re-elected Chad Robins as Class III director on June 10, 2025, with 80.95% support despite 19.05% withholding votes. The advisory vote on 2024 executive compensation passed with 98.46% approval, while ratification of Ernst & Young LLP as auditors for 2025 garnered 99.91% backing. Strong consensus signals investor confidence in leadership and oversight. No major dissent emerged.
10-Q
Q1 FY2025 results
Adaptive Biotechnologies posted Q1 FY2025 revenue of $52.4M, up 25% year-over-year from $41.9M, driven by MRD service revenue surging 39% to $39.2M on 36% higher clonoSEQ test volume, while Immune Medicine dipped 6% to $8.7M amid lower Genentech collaboration fees. Operating loss narrowed to $29.6M from $48.8M, with gross margin expanding to 67.6% from 56.9% thanks to cost efficiencies and higher volumes; diluted EPS improved to -$0.20 from -$0.33 on 149.2M shares, reconciling cleanly without dilution effects. Cash burn eased to $28.5M from $38.4M, leaving $232.8M in cash and equivalents against $133.6M revenue interest debt at 8.8% effective rate. Free cash flow turned positive at -$2.9M (derived), bolstering liquidity. Progress feels steady. Yet regulatory hurdles in immune therapies loom large.
IPO
Employees
Sector
Industry
ACET
Adicet Bio, Inc.
0.75-0.11
ADAP
Adaptimmune Therapeutics plc
0.05+0.00
ADTX
Aditxt, Inc.
0.11-0.02
ANAB
AnaptysBio, Inc.
36.12-0.04
APVO
Aptevo Therapeutics Inc.
1.42-0.04
AXIM
Axim Biotechnologies, Inc.
0.01+0.00
IMA
ImageneBio, Inc.
8.79+0.09
MRKR
Marker Therapeutics, Inc.
0.97-0.04
RAPT
RAPT Therapeutics, Inc.
29.78-0.35
ZIVO
Zivo Bioscience, Inc.
16.99-0.01